BYBurcu Yigit

Burcu Yigit

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Burcu Yigit has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Cox Terhorst

    Division of Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    3 shared publications
  • Ninghai Wang

    Division of Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts

    3 shared publications
  • Nicholas Chiorazzi

    Karches Center for Oncology Research, The Feinstein Institute for Medical Research, Manhasset, New York

    2 shared publications
  • Pablo Engel

    Faculty of Medicine and Health Sciences, Biomedical Sciences University of Barcelona Spain

    2 shared publications
  • Roland W. Herzog

    Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana

    2 shared publications
  • Shih-Shih Chen

    Karches Center for Oncology Research, The Feinstein Institute for Medical Research, Manhasset, New York

    2 shared publications

Latest Publications

  • SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer

    by Burcu Yigit, Ninghai Wang, Elisa Ten Hacken, Shih-Shih Chen, Atul K. Bhan, Abel Suarez-Fueyo, Eri Katsuyama, George C. Tsokos, Nicholas Chiorazzi, Catherine J. Wu, et al.

    The tumor microenvironment in leukemia and solid tumors induces a shift of activated CD8+ cytotoxic T cells to an exhausted state, characterized by loss of proliferative capacity and impaired immunologic synapse formation. Efficient strategies and targets need to be identified to overcome T-cell exhaustion and further improve overall responses in the clinic. Here, we took advantage of the Eμ-TCL1 chronic lymphocytic leukemia (CLL) and B16 melanoma mouse models to assess the role of the homophilic cell-surface receptor SLAMF6 as an immune-checkpoint regulator. The transfer of SLAMF6+ Eμ-TCL1 cells into SLAMF6−/− recipients, in contrast to wild-type (WT) recipients, significantly induced expansion of a PD-1+ subpopulation among CD3+CD44+CD8+ T cells, which had impaired cytotoxic functions. Conversely, administering anti-SLAMF6 significantly reduced the leukemic burden in Eμ-TCL1 recipient WT mice concomitantly with a loss of PD-1+CD3+CD44+CD8+ T cells with significantly increased effector functions. Anti-SLAMF6 significantly reduced leukemic burden in the peritoneal cavity, a niche where antibody-dependent cellular cytotoxicity (ADCC) is impaired, possibly through activation of CD8+ T cells. Targeting of SLAMF6 affected tumor growth not only in B cell–related leukemia and lymphomas but also in nonhematopoietic tumors such as B16 melanoma, where SLAMF6 is not expressed. In vitro exhausted CD8+ T cells showed increased degranulation when anti-human SLAMF6 was added in culture. Taken together, anti-SLAMF6 both effectively corrected CD8+ T-cell dysfunction and had a direct effect on tumor progression. The outcomes of our studies suggest that targeting SLAMF6 is a potential therapeutic strategy.


  • SLAMF6 in health and disease: Implications for therapeutic targeting

    by Burcu Yigit, Ninghai Wang, Roland W. Herzog, Cox Terhorst


  • Open Access

    A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells

    by Burcu Yigit, Peter J. Halibozek, Shih-Shih Chen, Michael S. O’keeffe, Jon Arnason, David Avigan, Valter Gattei, Atul Bhan, Osman Cen, Richard Longnecker, et al.

    A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells